EYPT Stock Overview
A clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EyePoint Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.38 |
| 52 Week High | US$30.99 |
| 52 Week Low | US$5.67 |
| Beta | 1.6 |
| 1 Month Change | -20.78% |
| 3 Month Change | -55.96% |
| 1 Year Change | 43.43% |
| 3 Year Change | -1.78% |
| 5 Year Change | -43.15% |
| Change since IPO | -70.32% |
Recent News & Updates
Recent updates
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01Shareholder Returns
| EYPT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.1% | 0.4% | 1.2% |
| 1Y | 43.4% | 17.1% | 20.6% |
Return vs Industry: EYPT exceeded the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: EYPT exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| EYPT volatility | |
|---|---|
| EYPT Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EYPT's share price has been volatile over the past 3 months.
Volatility Over Time: EYPT's weekly volatility has decreased from 29% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 121 | Jay Duker | eyepointpharma.com |
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
EyePoint Pharmaceuticals, Inc. Fundamentals Summary
| EYPT fundamental statistics | |
|---|---|
| Market cap | US$488.55m |
| Earnings (TTM) | -US$78.91m |
| Revenue (TTM) | US$50.02m |
9.8x
P/S Ratio-6.2x
P/E RatioIs EYPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYPT income statement (TTM) | |
|---|---|
| Revenue | US$50.02m |
| Cost of Revenue | US$85.63m |
| Gross Profit | -US$35.61m |
| Other Expenses | US$43.30m |
| Earnings | -US$78.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | -71.20% |
| Net Profit Margin | -157.77% |
| Debt/Equity Ratio | 0% |
How did EYPT perform over the long term?
See historical performance and comparison